Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Antiasthma Drugs: Muscarinic Receptor Antagonists

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to Simulation-based Training for Interventional Radiology and Opportunities for Improving the Educational Paradigm.

Techniques in vascular and interventional radiology·2021

Same author

Ultrasound guidance in accessing the afferent limb of a modified Roux-en-Y choledochojejunostomy for percutaneous dilation of biliary strictures.

Journal of vascular and interventional radiology : JVIR·2001

Same author

The decrease of virgin olive oil flavor produced by high malaxation temperature is due to inactivation of hydroperoxide lyase.

Journal of agricultural and food chemistry·1999

Same author

Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·1999

Same author

Differences in the immune response against ruminant chlamydial strains in a murine model.

Veterinary research·1999

Same author

[The Helicobacter pylori adhesion gene: relation with the origin of the isolates and associated disease].

Enfermedades infecciosas y microbiologia clinica·1999

Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026

Same journal

Gastrointestinal stenosis: an underrecognized complication of CARMIL2 deficiency.

Allergologia et immunopathologia·2026

Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026

Same journal

Vitamin B12 allergy and desensitization.

Allergologia et immunopathologia·2026

Same journal

Chronic HBV infection, stemness pathways, and compromised immune surveillance in HCC development.

Allergologia et immunopathologia·2026

Same journal

Application of FeNO in the diagnostic and therapeutic algorithm of pediatric asthma: From chronic cough and wheeze to personalized management.

Allergologia et immunopathologia·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 25, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Omalizumab beyond asthma.

J Sanchez¹, R Ramirez, S Diez

¹Group of Clinical and Experimental Allergology (GACE), Medellín, Colombia.

Allergologia Et Immunopathologia

|January 24, 2012

Summary

This summary is machine-generated.

Omalizumab effectively treats asthma by blocking immunoglobulin E (IgE). While promising for other IgE-mediated diseases like atopic dermatitis, more research is needed to confirm its efficacy and safety.

Related Experiment Videos

Last Updated: May 25, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

Immunology
Allergology
Pharmacology

Background:

Omalizumab is a proven therapy for asthma, reducing symptoms and corticosteroid use.
Its mechanism involves blocking immunoglobulin E (IgE) and secondary pathways.
The role of IgE in other diseases suggests potential therapeutic applications for omalizumab.

Purpose of the Study:

To review studies on omalizumab's use in non-asthma IgE-mediated diseases.
To evaluate omalizumab's potential in conditions like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders.

Main Methods:

Literature search of PUBMED, EMBASE, and LILACS databases.
Inclusion of studies on omalizumab treatment for allergic and other diseases.
Focus on articles published in English, Spanish, or Portuguese.

Main Results:

Current evidence is insufficient for routine omalizumab use beyond asthma.
Preliminary studies suggest potential benefits in atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders.
Further controlled trials are necessary to establish efficacy and safety.

Conclusions:

Omalizumab's efficacy in IgE-mediated diseases other than asthma requires more investigation.
Atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders show promise for omalizumab therapy.
Robust clinical trials are essential to validate omalizumab's role in these conditions.